The reported EPS is dominated by a one-time gain and does not reflect operating performance. Focus on the upcoming Phase 3 initiation for EDG-7500 and Phase 2 data for EDG-15400 as the next catalysts. The $1.744 billion cash position provides ample runway for pipeline advancement.
Drugs in focus
EWTX drug pipeline →EDG-15400
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years
- Next catalyst
- None dated
What to watchEDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $38.87entry
- T+1 · 11d ago +15.87%α +15.56% · $45.04
- T+5 · 5d ago +17.88%α +14.59% · $45.82
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Edgewise Therapeutics reported Q3 2026 net income of $1.166 billion ($9.65 diluted EPS), driven by a $1.348 billion gain on the sale of sevasemten to Servier, versus a net loss of $40.7 million a year ago. The company ended the quarter with $1.744 billion in cash and securities, initiated its Phase 2 EQUINOX-HFpEF trial for EDG-15400, and expects to start a Phase 3 trial for EDG-7500 in HCM by year-end 2026. The reported EPS of $9.65 far exceeded the consensus estimate of $2.51, but this reflects a one-time gain, not recurring operations.
Key Financial Metrics
Key Facts
- Net income of $1,166.2 million ($9.65 diluted EPS) vs net loss of $40.7 million ($0.39 loss per share) in Q3 2025
- Gain on sevasemten sale of $1.348 billion recognized in Q3 2026
- Cash, cash equivalents and marketable securities of $1,743.9 million as of September 30, 2026
- Phase 3 trial for EDG-7500 in HCM on track to initiate by year-end 2026
- First patient dosed in Phase 2 EQUINOX-HFpEF trial of EDG-15400
- R&D expenses decreased to $31.6 million from $37.5 million year-over-year, reflecting lower sevasemten costs
- G&A expenses increased to $14.6 million from $9.4 million year-over-year
Financial Impact
Net income of $1.166 billion vs consensus EPS estimate of $2.51, driven by a one-time $1.348 billion gain on asset sale
Risk Factors
- No revenue from product sales; company is pre-commercial
- Substantial dependence on success of EDG-7500 and EDG-15400 clinical programs
- Milestone payments from Servier transaction are contingent and not guaranteed
- Operating expenses may increase as clinical programs advance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-122654 |
| Document: tm2628556d1_8k.htm | 0001104659-26-122654 |
| Document: 0001104659-26-122654-index-headers.html | 0001104659-26-122654 |
| Document: 0001104659-26-122654-index.html | 0001104659-26-122654 |
| Document: 0001104659-26-122654.txt | 0001104659-26-122654 |
| 8-K Data (Synthetic) | 0001104659-26-122654 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry $43.68 Now $43.68 +0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers